Avacta Group Regulatory News (AVCT)

4 Apr 2007 07:00

Avacta Group Plc

Product Launch

ViVax Toolkit¢â€ž¢ for structural analysis of vaccines

Avacta Group Plc ("Avacta" or the "Group") which provides advanced biophysics technology and services to the biopharmaceutical, pharmaceutical, security, and clinical diagnostic sectors, announces the launch of a new service for the biopharmaceutical industry.

Avacta's ViVax Toolkit¢â€ž¢ is designed to help companies foresee problems in the drug development process before they arise and in doing so save time and money. It utilises multiple biophysical techniques for the analysis of viral and other types of vaccines, to assist in the development of new therapeutics, optimise their manufacture and successfully navigate the regulatory process.

This has been developed to address a critical unmet need for detailed but rapid analysis of complex biological entities, in response to requests from existing clients and through consultation with others in the sector. Throughout the process of bringing a vaccine to market, from the initial research stages through to quality control checks of the end product, there is a strict regulatory requirement for the characterisation of materials to ensure that the final drug products are produced consistently.

The ViVax Toolkit¢â€ž¢ will be delivered as an additional high value outsourcing service and future revenues are expected to reflect the significant savings in time and costs for customers in this high value sector through the provision of cost effective and rapid biophysical techniques.

Prof. Alastair Smith, Avacta Group plc Chief Executive Officer, commented:

"We are confident that this new service, which builds upon existing Avacta services, expertise and technology, will be readily adopted by biopharmaceutical companies worldwide focused on developing the `well characterized molecules' required by regulators.

"The ViVax Toolkit¢â€ž¢ will provide viral, cancer and other types of vaccine developers with a powerful and rapid method of characterising their materials for regulatory approval, and is an important new service for the sector with significant far-reaching opportunities."

4 April 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk